Immunoassay Market Poised for 6% CAGR Growth to $47.5B by 2031

  • Global immunoassay market projected to grow from $35.5B in 2026 to $47.5B by 2031, a 6% CAGR.
  • Growth driven by rising prevalence of infectious diseases, cancer, and chronic disorders.
  • Advances in multiplex and digital immunoassay platforms enable detection of multiple biomarkers from minimal samples.
  • Automation and point-of-care testing expanding market reach beyond centralized laboratories.
  • Key players include Roche, Abbott, Siemens Healthineers, and Thermo Fisher Scientific.

The immunoassay market is evolving with technological advancements in multiplexing and digital detection, alongside growing demand for decentralized testing. The market's growth is underpinned by rising disease burdens and the need for early disease detection, with key players focusing on innovation and strategic partnerships to strengthen their positions. The shift towards automation and point-of-care testing is reshaping the diagnostic landscape, extending testing capabilities beyond centralized laboratories.

Technology Adoption
How the shift to multiplex and digital immunoassay platforms will affect diagnostic accuracy and market penetration.
Regional Expansion
Whether Asia-Pacific can sustain its high growth rate driven by expanding healthcare infrastructure and diagnostic testing volumes.
Cost Barriers
The pace at which cost barriers to adoption of advanced immunoassay technologies will be overcome.